BELITE BIO, INC current report, Q2 FY2023

Full document

Belite Bio, Inc. Form 6-K Summary

Business Context and Reporting Period

Belite Bio, Inc., a foreign private issuer, furnished this Form 6-K for June 2023. On June 16, 2023, the company entered into a Sales Agreement with SVB Securities LLC and Cantor Fitzgerald & Co. to facilitate an at-the-market offering of American Depositary Shares (ADSs), with each ADS representing one ordinary share.

Offering Terms and Financial Impact

  • The company may offer and sell ADSs with aggregate gross proceeds of up to $100 million under its effective Form F-3 registration statement.
  • The company is not obligated to sell any ADSs, and the agents are not required to sell a specified amount.
  • The sales agents will receive a commission equal to 3.0% of gross proceeds from ADSs sold through them.
  • No proceeds had been reported as raised in the filing text.
  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics.

Material Changes, Outlook, and Risks

  • Material event: the company established a potential $100 million equity financing facility.
  • Sales may occur from time to time through market transactions or, with company consent, negotiated transactions.
  • The agreement may be terminated by either the company or the agents with 10 days’ prior notice and will otherwise terminate when all covered ADSs are sold or as otherwise permitted under the agreement.
  • The offering could result in dilution to existing shareholders if ADSs are issued and sold.
  • The company agreed to indemnify and provide contribution to the agents for certain liabilities, including liabilities under the Securities Act and Exchange Act.
  • The filing provides no specific financial guidance, operating outlook, or management commentary beyond the financing arrangement.

Important Facts to Verify

  • Whether any ADSs were subsequently sold and the resulting gross and net proceeds.
  • The number of ADSs issued, offering prices, and potential dilution to existing shareholders.
  • Use of proceeds and the company’s updated cash runway and liquidity position.
  • The full Sales Agreement and any subsequent Form 6-K or other filings describing amendments, sales, or termination.
  • Any risks or contingencies associated with the company’s ability to fund its operations and development programs.